Form 4: United Therapeutics Executive Exercises Share Tracking Awards and Sells Shares

Paul A. Mahon, EVP & General Counsel at United Therapeutics, exercised share tracking awards and sold the underlying shares on December 5, 2024, according to a recent SEC filing.

Summary

• Paul A. Mahon, an executive at United Therapeutics, exercised 7,700 share tracking awards on December 5, 2024.
• These awards were exercised at a price of $163.30 per share.
• Concurrently, Mr. Mahon sold 7,700 shares of common stock at a price of $374.37 per share.
• The transactions were executed under a pre-arranged 10b5-1 trading plan established on June 20, 2024.
• Following these transactions, Mr. Mahon directly owns 36,710 shares of common stock and 45,050 share tracking awards.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction by an executive under a pre-arranged plan, with no indication of positive or negative sentiment.

Industry Context

This is a routine filing related to executive compensation and trading activity, which is common in publicly traded companies. The use of 10b5-1 plans is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of share tracking awards and 10b5-1 trading plans is a common practice among publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Many companies, such as Amgen, Gilead Sciences, and Biogen, utilize similar compensation structures for their executives.
• The specific terms and conditions of these awards can vary, but the general principle of aligning executive interests with shareholder value is consistent across the industry.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-arranged plan and do not indicate a change in the company's fundamentals.

Key Dates

Keywords

share tracking awards, insider trading, SEC Form 4, executive compensation, stock sale, 10b5-1 plan, United Therapeutics, UTHR